Dermata Therapeutics, Inc. (DRMA) - Dilution Analysis

10-Q filing | 3.9M shares outstanding

10-K filing | 4.0M shares outstanding

S-3 filing: This S-3 filing from Dermata Therapeutics, Inc. relates to the resale of up to 6,207,730 shares of common stock by selling stockholders, including shares and shares issuable upon the exercise of warrants from a private placement.

10-Q filing | 0.7M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 6,378,118 → 637,811

10-Q filing | 6.4M shares outstanding

S-3 filing: SEC filing containing information about shares of common stock outstanding and potential offerings related to warrants and shares held by various entities.

8-K filing: Dermata Therapeutics, Inc. closed a private placement on March 28, 2025, issuing new warrants and receiving $6.2 million in gross proceeds from the exercise of existing warrants. ($6.2M proceeds)

10-K filing | 2.5M shares outstanding

8-K filing: Dermata Therapeutics, Inc. completed a private placement on January 23, 2025, issuing 1,935,412 shares of common stock, pre-funded warrants to purchase up to 72,468 shares of common stock, and warrants to purchase up to 2,007,880 shares of common stock, with net proceeds to the company of approximately $2.4 million. ($2.47M proceeds)

10-Q filing | 1.7M shares outstanding

8-K filing: Dermata Therapeutics, Inc. closed a private placement on September 17, 2024, issuing pre-funded warrants and Series A and B warrants to purchase common stock, with net proceeds to the company of approximately $3.0 million. ($3.5M proceeds)

10-Q filing | 0.7M shares outstanding

S-3 filing: This prospectus covers the resale or other disposition by the Selling Stockholders identified in the table below of up to an aggregate 1,068,816 shares of our Common Stock issuable upon the exercise of the Warrants.

8-K filing: Dermata Therapeutics entered into inducement letter agreements with warrant holders to exercise existing warrants at a reduced price of $5.16 per share, resulting in gross proceeds of approximately $2.66 million, and the issuance of new Series A and Series B warrants. ($2.66M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 770,115 → 51,341

10-Q filing | 3.9M shares outstanding

10-K filing | 0.8M shares outstanding

S-3 filing: This S-3 filing relates to the resale of common stock issuable upon the exercise of warrants held by selling stockholders, who acquired their securities in a private placement.

8-K filing: Dermata Therapeutics, Inc. entered into an inducement offer letter agreement with a warrant holder to exercise existing warrants at a reduced price, resulting in the issuance of new series A and B warrants and expected gross proceeds of approximately $2.26 million for general corporate purposes. ($2.26M proceeds)

10-Q filing | 3.2M shares outstanding

10-Q filing | 3.2M shares outstanding

S-1 filing: This prospectus relates to the resale or other disposition from time to time by the selling stockholders identified in this prospectus of up to 856,938 shares of Common Stock issuable upon exercise of the Warrants.

8-K filing: Dermata Therapeutics, Inc. entered into a securities purchase agreement to sell and issue 458,555 shares of common stock and 342,322 pre-funded warrants, along with warrants to purchase up to 800,877 shares, for gross proceeds of approximately $1.8 million. ($1.83M proceeds)

10-Q filing | 2.4M shares outstanding

8-K filing: Dermata Therapeutics, Inc. entered into a securities purchase agreement to sell 85,000 shares of common stock, pre-funded warrants to purchase 1,533,123 shares of common stock, Series A warrants to purchase 1,618,123 shares of common stock, and Series B warrants to purchase 1,618,123 shares of common stock in a public offering that closed on March 20, 2023, with net proceeds of approximately $4.2 million to be used for general corporate purposes.

S-1/A filing: This S-1/A filing, dated March 16, 2023, is for an offering of common stock, Series A warrants, Series B warrants, placement agent warrants and pre-funded warrants by DRMA.

S-1/A filing: This S-1/A filing relates to an offering of shares of common stock, common warrants, and pre-funded warrants with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

8-K filing: Stock split 1-for-16 | Outstanding: 770,115 → 48,132

S-1/A filing: This is an S-1/A filing for offering of 1,913,875 shares of common stock, together with warrants to purchase 1,913,875 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 1,913,875 shares of common stock. The placement agent warrants will be exercisable upon issuance and will expire five years from the commencement of sales under this offering.

S-1 filing: This S-1 filing outlines the offering of common stock, common warrants, and pre-funded warrants, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

10-K filing | 5.0M shares outstanding

S-3 filing: Dermata Therapeutics, Inc. files an S-3 for mixed shelf offering of common stock, preferred stock, debt securities, subscription rights, and units, with an aggregate offering price not to exceed $100,000,000.

10-Q filing | 12.1M shares outstanding

10-Q filing | 10.1M shares outstanding

10-Q filing | 8.4M shares outstanding

S-1 filing: This prospectus relates to the resale from time to time, by the selling stockholder identified in this prospectus under the caption "Selling Stockholder," of up to 7,547,170 shares of our common stock

8-K filing: Dermata Therapeutics, Inc. completed a private placement on April 25, 2022, issuing 898,585 shares of common stock, pre-funded warrants to purchase up to 2,875,000 shares, and warrants to purchase up to 3,773,585 shares, with gross proceeds of approximately $5.0 million. ($5.0M proceeds)

10-K filing | 0.5M shares outstanding

S-1/A filing: The filing relates to an S-1/A amendment for a proposed offering of Common Stock and Pre-Funded Warrants with a maximum aggregate offering price of $11,500,000.

S-1 filing: Dermata Therapeutics, Inc. is offering units, each consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock.

10-Q filing | 6.5M shares outstanding

10-Q filing | 6.5M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of 1,875,000 Units, each consisting of one share of common stock and one warrant, at a public offering price of $8.00 per unit.

S-1/A filing: This S-1/A filing describes an offering of 1,875,000 shares of common stock at an assumed price of $8.00 per share, with an option for underwriters to purchase an additional 281,250 shares. The company intends to use the net proceeds for clinical trials, drug development, manufacturing, and general corporate purposes.

S-1/A filing: This is an S-1/A filing for an initial public offering of 1,875,000 shares of common stock at an assumed price of $8.00 per share. The underwriters have a 45-day option to purchase up to an additional 281,250 shares. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol 'DRMA'.

S-1 filing: This is an S-1 filing for an initial public offering of common stock underwritten by Maxim Group LLC. The company has applied to list its common stock on the Nasdaq Capital Market under the symbol DRMA.